Free Trial

Carisma Therapeutics (CARM) Earnings Date, Estimates & Call Transcripts

Carisma Therapeutics logo
$0.0002 0.00 (0.00%)
As of 05/11/2026 02:06 PM Eastern

Carisma Therapeutics Earnings Summary

Carisma Therapeutics posted Q3 2025 earnings on November 12, 2025, reporting an EPS of $1.07. Quarterly revenue was reported to be $45.25 million. With a trailing EPS of $0.73 and a P/E Ratio of 0.00, Carisma Therapeutics' earnings are expected to grow next year, from ($1.32) to ($1.26) per share.

Latest Q3
Earnings Date
Nov. 12Estimated
Actual Revenue
(Nov. 12)
$45.25M
Get Carisma Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carisma Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

CARM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CARM Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Carisma Therapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate
($1.32) EPS
Next Year EPS Consensus Estimate
($1.26) EPS

Carisma Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/12/2025Q3 2025-$1.07-$1.07-$45.25M
5/13/2025Q1 2025-$0.17-$0.22 -$0.05-$0.22$2.47M$3.65M
11/7/2024Q3 2024-$0.31-$0.31--$0.31-$3.39M
8/8/2024--$0.36-$0.27+$0.09-$0.27$3.65M$9.20M

Data powered by Fiscal.ai.

Carisma Therapeutics Earnings - Frequently Asked Questions

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earning data on Wednesday, November 12, 2025. Learn more on CARM's earnings history.

Carisma Therapeutics (NASDAQ:CARM) has a recorded annual revenue of $10.77 million.

Carisma Therapeutics (NASDAQ:CARM) has a recorded net income of -$60.48 million. CARM has generated $0.73 earnings per share over the last four quarters.

Carisma Therapeutics (NASDAQ:CARM) has a trailing price-to-earnings ratio of 0.00.

Carisma Therapeutics' earnings are expected to grow from ($1.32) per share to ($1.26) per share in the next year.


This page (NASDAQ:CARM) was last updated on 5/12/2026 by MarketBeat.com Staff.
From Our Partners